<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02960698</url>
  </required_header>
  <id_info>
    <org_study_id>C16-07</org_study_id>
    <secondary_id>2016-A00936-45</secondary_id>
    <nct_id>NCT02960698</nct_id>
  </id_info>
  <brief_title>Impulsivity in Tourette Syndrome : Behavioral and Neuroimaging Study</brief_title>
  <acronym>COGIT</acronym>
  <official_title>Identifying the Neural Correlates of Cognitive Impulsivity in Patients With Tourette Syndrome. &quot;COGIT&quot;.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tourette syndrome (TS) is characterized by the presence of multiple vocal and motor tics.&#xD;
      Behavioral disorders associated with TS are common, particularly impulsivity, anti-sociality&#xD;
      and socially inappropriate behavior. Specifically, cognitive impulsivity could be the source&#xD;
      of these troubles. Its anatomical substrates is based on connections between frontal and&#xD;
      striatal areas.&#xD;
&#xD;
      Initially, a battery of behavioral tests measuring different types of impulsivity (motor,&#xD;
      cognitive and decision) will be administered on three groups of subjects: TS: 80 patients (40&#xD;
      patients treated and 40 untreated) and 40 healthy volunteers.&#xD;
&#xD;
      Then, investigators will study the fronto-striatal connections in the TS group of 80 patients&#xD;
      (40 patients treated and 40 untreated) compared to 40 healthy volunteers using neuroimaging&#xD;
      techniques (3T MRI). The techniques used will be functional connectivity study of &quot;resting&#xD;
      state&quot; MRI (RS-fMRI) combined with a reconstruction of white matter fibers by diffusion&#xD;
      tensor imaging (DTI). Behavioral performance will be correlated with the correlation imaging&#xD;
      data to highlight the functional anatomical substrates of impulsivity in patients with TS.&#xD;
&#xD;
      Finally, investigators will look specifically using functional MRI activation, the anatomical&#xD;
      and functional substrates of the three types of impulsivity (motor, cognitive and&#xD;
      decision-making).&#xD;
&#xD;
      Through this study, investigators hope to elucidate the anatomical and functional bases of&#xD;
      cognitive impulsivity in patients with TS and thus lay the basis for more targeted&#xD;
      treatments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 14, 2016</start_date>
  <completion_date type="Actual">April 24, 2018</completion_date>
  <primary_completion_date type="Actual">April 24, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>behavior performance (percentage of correct responses and reaction time)</measure>
    <time_frame>up to one month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>BOLD signal of functional MRI scan</measure>
    <time_frame>up to one month</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Tourette Syndrome</condition>
  <arm_group>
    <arm_group_label>TREATED PATIENT WITH TOURETTE SYNDROME</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>comportemental tasks included impulsivity tests will performed at V1 Resting state IRM will be performed at V2 40 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UNTREATED PATIENT WITH TOURETTE SYNDROME</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>comportemental tasks included impulsivity tests will performed at V1 Resting state IRM will be performed at V2 40 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>comportemental tasks included impulsivity tests will performed at V1 Resting state IRM will be performed at V2 80 subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IRM and comportemental tasks</intervention_name>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>TREATED PATIENT WITH TOURETTE SYNDROME</arm_group_label>
    <arm_group_label>UNTREATED PATIENT WITH TOURETTE SYNDROME</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For all subjects:&#xD;
&#xD;
          -  ≥ about 18 and 65 years old&#xD;
&#xD;
          -  About receiving Social Security or universal health coverage or any equivalent plan&#xD;
&#xD;
          -  About who signed the informed consent&#xD;
&#xD;
        For TS patients treated :&#xD;
&#xD;
          -  TS principal diagnosis, based on the DSM-5 criteria&#xD;
&#xD;
          -  Stable pharmacological treatment at least 4 weeks prior to study entry;&#xD;
&#xD;
          -  Possibility of controlling the majority tics of the upper part of the body lying down&#xD;
             for at least 10 minutes (frequency tics on YGTSS &lt;3).&#xD;
&#xD;
        For TS patients untreated:&#xD;
&#xD;
          -  TS principal diagnosis, based on the DSM-5 criteria&#xD;
&#xD;
          -  No psychotropic treatments (neuroleptics, antidepressants or anxiolytics) mentioned at&#xD;
             the time of inclusion.&#xD;
&#xD;
          -  Possibility of controlling the majority tics of the upper part of the body lying down&#xD;
             for at least 10 minutes (frequency tics on YGTSS &lt;3).&#xD;
&#xD;
        In healthy volunteers:&#xD;
&#xD;
          -  Normal neurological examination (evaluation MINI).&#xD;
&#xD;
          -  No regular pharmacological treatment with the exception of birth control pills for&#xD;
             women&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For all patients TS:&#xD;
&#xD;
          -  Age &lt;18 years.&#xD;
&#xD;
          -  Presence One of the following diagnoses Axis I DSM-5: schizophrenic disorders or&#xD;
             current psychotic episode or in the past, bipolar disorder, current major depressive&#xD;
             disorder autism spectrum.&#xD;
&#xD;
          -  Abus Psychotropic substance dependency or a psychotropic substance, including alcohol&#xD;
             (except nicotine).&#xD;
&#xD;
          -  Support Regular / chronic drugs and other xenobiotics tropic psychotropic.&#xD;
&#xD;
          -  Support Treatment with benzodiazepines in the 4 months prior to study entry. -Patient&#xD;
             Subject to a measure of legal protection (guardianship, curatorship or safeguard&#xD;
             justice). -No private freedom by administrative decision or justice.&#xD;
&#xD;
          -  No Unable to consent and are not subject to a protection measure.&#xD;
&#xD;
          -  Participation In other biomedical research or subjected to an exclusion period for&#xD;
             another search.&#xD;
&#xD;
          -  Problems General understanding.&#xD;
&#xD;
          -  Weight Of more than 150 kg.&#xD;
&#xD;
          -  Inability To maintain an upper portion of movement of the body lying down for at least&#xD;
             10 minutes (frequency tics on YGTSS&gt; 3).&#xD;
&#xD;
        In healthy volunteers (HV):&#xD;
&#xD;
          -  psychiatric disorders, cognitive impairment assessed by the MINI scale.&#xD;
&#xD;
          -  About not being able to understand the tasks&#xD;
&#xD;
          -  age &lt;18 years.&#xD;
&#xD;
          -  No Subject to a measure of legal protection (guardianship, curatorship or safeguard&#xD;
             justice).&#xD;
&#xD;
          -  Participation In other biomedical research or subjected to an exclusion period for&#xD;
             another search.&#xD;
&#xD;
          -  Not Unable to consent and are not subject to a protection measure.&#xD;
&#xD;
          -  Not private freedom by administrative decision or court&#xD;
&#xD;
        For TS patients (treated and untreated) and HV&#xD;
&#xD;
          -  relative to MRI 3Tesla : pacemaker, cardiac cell or neural stimulator ferromagnetic&#xD;
             surgical clips body intraocular or intracranial metallic foreign cochlear implant&#xD;
             artificial heart valve or arterial metal surgical equipment metallic material that&#xD;
             could concentrate the radio frequency pulses pregnant women, women in labor or&#xD;
             lactating aneurism Standing up the eyelids vascular malformation of the brain&#xD;
&#xD;
          -  Topic not wishing to be informed of a clinically significant abnormality discovered&#xD;
             during the realization of MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>HARTMANN</name>
      <address>
        <city>Paris</city>
        <state>ILE DE France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 27, 2016</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2016</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cognitive impulsivity</keyword>
  <keyword>IRM</keyword>
  <keyword>Tourette Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tourette Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Impulsive Behavior</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

